@article{8687981120594ed1abd4470f9e8aeb0c,
title = "Thromboembolic risk with IVIg: Incidence and risk factors in patients with inflammatory neuropathy",
abstract = "Our objective was to evaluate whether IV immunoglobulin (IVIg) increases the risk of thromboembolic events in neurology outpatients with inflammatory neuropathies, as there is conflicting evidence supporting this hypothesis, mainly from non-neurologic cohorts. We investigated this question over 30 months in our cohort of patients with inflammatory neuropathies receiving regular IVIg and found a greater incidence of arterial and venous thromboembolic events than population-based rates determined by hospital admissions data. Vascular risk factors were more common in the event group but there were no IVIg administration factors that contributed to the risk. This study suggests that IVIg may have a small but contributory role in determining thromboembolic risk in the inflammatory neuropathy cohort and more evidence is required before it is clear whether the current primary prevention guidelines are appropriate in this group of patients.",
author = "Mahima Kapoor and Jennifer Spillane and Christina Englezou and Scherezade Sarri-Gonzalez and Robert Bell and Alexander Rossor and Hadi Manji and Reilly, {Mary M.} and Lunn, {Michael P.} and Aisling Carr",
note = "Funding Information: J. Spillane, C. Englezou, S. Sarri-Gonzalez, M. Kapoor, and R. Bell report no disclosures relevant to the manuscript. A. Rossor is funded by a Wellcome Trust Postdoctoral Fellowship for Clinicians (110043/Z/15/Z). H. Manji reports no disclosures relevant to the manuscript. M. Reilly received a Medical Research Council Centre grant (G0601943) and support from the National Institutes of Neurologic Diseases and Stroke and Office of Rare Diseases (U54NS065712). M. Lunn was a Primary Investigator in studies for CSL Behring, UCB Pharma, Novartis, and Octapharma, and has received ad hoc consulting fees from CSL Behring, UCB, and an honorarium from Terumo BCT. A. Carr reports Grifols sponsorship for attendance at meeting and honorarium from CSL and Lupin for an advisory role. Go to https://n.neurology.org/lookup/doi/10.1212/WNL.0000000000008742 for full disclosures. Funding Information: This research was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. Funding Information: The Article Processing Charge was funded by Wellcome Trust and UKRI. Publisher Copyright: {\textcopyright} American Academy of Neurology.",
year = "2020",
month = feb,
day = "11",
doi = "10.1212/WNL.0000000000008742",
language = "English",
volume = "94",
pages = "E635--E638",
journal = "Neurology",
issn = "0028-3878",
publisher = "Ovid Technologies (Wolters Kluwer) - American Academy of Neurology",
number = "6",
}